Afatinib is a targeted cancer therapy known as a tyrosine kinase inhibitor (TKI). It specifically inhibits the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) pathways, which are often overactive in various cancers. By blocking these pathways, afatinib helps to impede the growth and spread of cancer cells.
